Drug Discovery Assay Services Assay: Bronchodilatation in secondary COPD human airways (Adrenoceptor)

Code: B059
Available | Usually dispatched within 24 hours
Prices apply to customers in North America only
Loading...
Be the first to review Drug Discovery Assay Services Assay: Bronchodilatation in secondary COPD human airways (Adrenoceptor). Write a review
Assay type:Respiratory
Tissue:Human Tertiary Or Lower Airways (COPD)
Target:Adrenoceptor
Control Compound:Isoprenaline
Study Type:Wire Myography
Functional Endpoint:Bronchodilatation

Assay Description

This assay assesses whether test compounds cause bronchodilation in COPD human airways with isoprenaline as a reference compound.

The airways of the respiratory tract offer resistance to the flow of air during inhalation and expiration. Any alterations to the airways (for example contractile state, increased mucus or inflammation of the airways) can affect airflow. Chronic Obstructive Pulmonary Disease (COPD) is the term given to a collection of airway disorders including bronchitis and emphysema. COPD is generally caused by an obstruction to airflow caused by a narrowing of the airways. Over time, the damage to the airways such as scarring, increased mucus and loss of elasticity also contribute to the restricted airflow and increased workload for the respiratory muscles.

Example assay graph

Image Legend

Figure 1: Cumulative concentration response curve to isoprenaline and its vehicle in isolated human COPD airways, pre-constricted with 3 x 10−7 M acetylcholine, demonstrating a concentration dependent relaxation response.

The Log EC50 = −7.62 ± 0.44 M (24 nM) (mean ± S.E.M), with a maximum relaxation response of

112.7 ± 22.83 % at 1 x 10−5 M.

Testing Information

Introduction

The specific results that will be provided are the effects of increasing concentrations of test articles on the contractile state of isolated COPD human airways.

Turnaround Time

10-12 weeks from sample receipt for n = 3 donors.

Timelines are a guide based on Biopta's standard tissue criteria; any client imposed deviations to the standard tissue criteria can alter the project timelines.

Test Article Requirements

Test article(s) to be provided by the Sponsor in storable aliquots at required test concentrations with information on diluent vehicle used. Stock solutions are prepared in distilled water unless otherwise requested. Bath volumes are 5 ml; Sponsor to provide sufficient test article to run the entire study.

Suggested Testing

In duplicate at 6 concentrations.

Study Outline

Rationale and Experimental Design

This assay assesses whether test compounds cause bronchodilation in COPD human airways with isoprenaline as a reference compound.

Exclusion Criteria

No specific exclusion criteria are in place other than to reject macroscopically diseased/necrotic tissue. Furthermore, tissues which do not respond to the standard pharmacology checks will be excluded.

Standardisation and Qualification

All individual airways are initially processed through standardisation and qualification procedures to ensure functionality, prior to starting the study protocol.

Airways are processed through a standardisation procedure to reduce signal variability prior to pharmacological intervention. This ensures that airways are maintained under appropriate physiological tension throughout the experiments.

Following standardisation, the airways are challenged with an appropriate bronchoconstrictive agent to ensure robust contractile responses.

Test tissues are then washed and the responses allowed to return to baseline.

Airways which pass the standardisation and qualification pass/fail criteria will then progress to the study protocol.

Bronchodilatation Assays

Agonist Bronchodilatation Assays

To assess the ability of each test article to elicit bronchodilatation, 6 point cumulative concentration response curves (CCRC's) will be performed for each test article. These CCRC's will be performed following pre-constriction with an appropriate bronchoconstrictive agent. A positive control compound and representative test article vehicle CCRC will also be run to allow direct comparison with test articles.

An example of the conditions assessed for 3 test articles are detailed below (each condition will be run in duplicate airways):

Representative test article vehicle CCRC

  • Test article 1 CCRC
  • Test article 2 CCRC
  • Test article 3 CCRC
  • Positive control CCRC

Supplementary Option

To assess the involvement of a specific receptor subtype in any observed responses, the concentration of test article eliciting the largest response can subsequently (following a wash out and recovery period) be tested in the presence of a specific antagonist. This supplementary option will incur an extra charge.

Antagonist Bronchodilatation Assays

Option 1 − IC50 determination

To assess the ability of each test article to antagonise an agonist mediated bronchorelaxation response, 6 point cumulative concentration response curves (CCRC's) will be performed for each test article. These CCRC's will be performed following pre-constriction and relaxation with an appropriate bronchorelaxant reference agonist. A positive control compound and representative test article vehicle CCRC will also be run to allow direct comparison with test articles.

An example of the conditions assessed for 3 test articles are detailed below (each condition will be run in duplicate airways):

  • Representative test article vehicle CCRC
  • Test article 1 CCRC
  • Test article 2 CCRC
  • Test article 3 CCRC
  • Positive control CCRC

Option 2 − pA2 determination

To assess the ability of a test article to antagonise an agonist mediated bronchorelaxation response; 6 point cumulative concentration response curves (CCRC's) will firstly be performed for the reference agonist, following pre-constriction with an appropriate bronchoconstrictive agent. Following a wash out and recovery period, vessels will be incubated with the test article (3 different concentrations of test article will be assessed), positive control or test article vehicle before the same 6 point cumulative concentration response curve will be repeated for the reference agonist.

An example of the conditions assessed for 3 test articles are detailed below (each condition will be run in duplicate airways):

  • Representative test article vehicle
  • Test article 1 concentration 1
  • Test article 1 concentration 2
  • Test article 1 concentration 3
  • Test article 2 concentration 1
  • Test article 2 concentration 2
  • Test article 2 concentration 3
  • Test article 3 concentration 1
  • Test article 3 concentration 2
  • Test article 3 concentration 3
  • Positive control

Analysis

Responses shall be expressed either in milligrams or grams tension, or as a % of the maximal contractile response (eg. KPSS). Statistical analysis (where appropriate) will be performed using GraphPad Prism, with the results being shown in graphical form in the final report.

Top